Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–9.

Loo YM, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022;14(635):eabl8124.

Robbie GJ, Criste R, Dall’acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53.

Yu XQ, Robbie GJ, Wu Y, et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother. 2017;61(1):e01020–e1116.

Oganesyan V, Gao C, Shirinian L, Wu H, Dall’Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr. 2008;64:700–4.

European Medicines Agency. Evusheld: EPAR - Product information. 2022. https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_en.pdf. Accessed 8 January 2024.

AstraZeneca. Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan. 2022. https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-for-covid-19-in-japan.html. Accessed 8 January 2024.

AstraZeneca Canada Inc. EVUSHELD. Tixagevimab and cilgavimab injection. Product monograph including patient medication information. 2022. https://covid-vaccine.canada.ca/info/pdf/evusheld-pm-en.pdf. Accessed 8 January 2024.

Australian Government Department of Health and Aged Care. Therapeutic Goods Administration. Evusheld. 2022. https://www.tga.gov.au/resources/auspmd/evusheld-0. Accessed 8 January 2024.

Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Eng J Med. 2023;388(1):89–91.

Arora P, Kempf A, Nehlmeier I, et al. Omicron sublineage BQ 1 1 resistance to monoclonal antibodies. Lancet Infect Dis. 2022;23(1):S1473-3099.

Wang Q, Li Z, Ho J, et al. Resistance of SARS-CoV-2 omicron subvariant BA 4.6 to antibody neutralisation. Lancet Infect Dis. 2022;22(12):1666–8.

United States Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us. Accessed 8 January 2024.

Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985–96.

Hobbs FDR, Montgomery H, Padilla F, et al. Outpatient treatment with AZD7442 (tixagevimab/cilgavimab) prevented COVID-19 hospitalizations over 6 months and reduced symptom progression in the TACKLE randomized trial. Infect Dis Ther. 2023;12(9):2269–87.

Forte-Soto P, Albayaty M, Brooks D, et al. Safety, tolerability and pharmacokinetics of half-life extended severe acute respiratorysyndrome coronavirus 2 neutralizing monoclonal antibodies AZD7442 (tixagevimab-cilgavimab) in healthy adults. J Infect Dis. 2023;227(10):1153–63.

Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188–200.

ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022;10(10):P972–84.

Clegg LE, Stepanov O, Schmidt S, et al. Consistency of AZD7442 (cilgavimab/tixagevimab) pharmacokinetics across prophylaxis and treatment and adult and pediatric participants: application of population pharmacokinetics to enable rapid decision-making during the COVID-19 pandemic. Open Forum Infect Dis. 2023. https://doi.org/10.1093/ofid/ofad500.464.

Okada H, Ishikawa K, Itoh Y, et al. Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults. J Infect Chemother. 2023;29:1061–7.

Akinosoglou K, Rigopoulos EA, Kaiafa G, et al. Tixagevimab/cilgavimab in SARS-CoV-2 prophylaxis and therapy: a comprehensive review of clinical experience. Viruses. 2022;15(1):118.

Elias LB, Jaber A, Manzano M, Leekoff M, Sylvester A, Tremblay MA. Real-world efficacy of COVID-19 pre-exposure prophylaxis with tixagevimab/cilgavimab in people with multiple sclerosis. Vaccines (Basel). 2023;11(12):1855.

Al Jurdi A, Morena L, Cote M, Bethea E, Azzi J, Riella LV. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am J Transplant. 2022;22(12):3130–6.

Angelico R, Romano F, Coppola L, et al. Effects of anti-COVID-19 vaccination and pre-exposure prophylaxis with tixagevimab-cilgavimab in kidney and liver transplant recipients. Medicina (Kaunas). 2023;59(12):2101.

Evans RA, Dube S, Lu Y, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health-Eur. 2023;35: 100747.

Ketkar A, Willey V, Pollack M, et al. Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study. Curr Med Res Opin. 2023;39(8):1–16.